Dario Melgari

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2664538/publications.pdf

Version: 2024-02-01

15 papers	251 citations	1307594 7 h-index	1058476 14 g-index
19 all docs	19 docs citations	19 times ranked	439 citing authors

#	Article	IF	Citations
1	Novel SCN5A p.Val1667Asp Missense Variant Segregation and Characterization in a Family with Severe Brugada Syndrome and Multiple Sudden Deaths. International Journal of Molecular Sciences, 2021, 22, 4700.	4.1	5
2	Distinct calcium/calmodulin-dependent serine protein kinase domains control cardiac sodium channel membrane expression and focal adhesion anchoring. Heart Rhythm, 2020, 17, 786-794.	0.7	8
3	Propranolol Attenuates Late Sodium Current in a Long QT Syndrome Type 3-Human Induced Pluripotent Stem Cell Model. Frontiers in Cell and Developmental Biology, 2020, 8, 761.	3.7	9
4	Microtubule polymerization state and clathrin-dependent internalization regulate dynamics of cardiac potassium channel. Journal of Molecular and Cellular Cardiology, 2020, 144, 127-139.	1.9	8
5	Rapid Characterization of hERG Channel Kinetics II: Temperature Dependence. Biophysical Journal, 2019, 117, 2455-2470.	0.5	38
6	Investigation of hERG1b Influence on hERG Channel Pharmacology at Physiological Temperature. Journal of Pharmacology and Pharmacotherapeutics, 2018, 9, 92-103.	0.4	10
7	Letter by Melgari et al Regarding Article, â€œIvabradine: Role in the Chronic Heart Failure Armamentariumâ€. Circulation, 2016, 134, e296-7.	1.6	1
8	Molecular basis of hERG potassium channel blockade by the class Ic antiarrhythmic flecainide. Journal of Molecular and Cellular Cardiology, 2015, 86, 42-53.	1.9	55
9	hERG potassium channel inhibition by ivabradine may contribute to QT prolongation and risk of torsades de pointes. Therapeutic Advances in Drug Safety, 2015, 6, 177-179.	2.4	10
10	hERG potassium channel inhibition by ivabradine requires channel gating. Journal of Molecular and Cellular Cardiology, 2015, 87, 126-128.	1.9	2
11	hERG Potassium Channel Blockade by the HCN Channel Inhibitor Bradycardic Agent Ivabradine. Journal of the American Heart Association, 2015, 4, .	3.7	72
12	Suppression of the hERG potassium channel response to premature stimulation by reduction in extracellular potassium concentration. Physiological Reports, 2014, 2, e12165.	1.7	8
13	Sensitivity of Flecainide Inhibition of hERG Channels to Channel Inactivation. Biophysical Journal, 2014, 106, 138a.	0.5	2
14	Investigation of the Influence of hERG 1b on hERG Channel Pharmacology. Biophysical Journal, 2013, 104, 297a.	0.5	0
15	Action Potential Clamp and Pharmacology of the Variant 1 Short QT Syndrome T618I hERG K+ Channel. PLoS ONE, 2012, 7, e52451.	2.5	23